Investors & Media

  • Webcast
    IONIS-HTT Rx Phase 1/2 Update Webcast
    03/02/18 11:00 am EST
  • Webcast
    Cowen Annual Health Care Conference
    03/13/18 10:40 am EDT
  • Webcast
    Ionis and Akcea Webcast on Inotersen Commercial Collaboration
    03/15/18 8:30 am EDT
  • Webcast
    17th Annual Needham Healthcare Conference
    03/27/18 11:30 am EDT

Company Profile

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan, Canada and Brazil for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen , an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Volanesorsen filings for marketing approval have been submitted in the U.S., EU and Canada. Inotersen is progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year Ionis Chief Business Officer Sarah Boyce will join
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , March 6, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Cowen Annual Health Care Conference on Tuesday, March 13, 2018
Toggle Summary IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
Phase 1/2 study first to demonstrate disease-modifying potential Up to ~60% reduction (mean ~40%) in the mutant huntingtin protein (mHTT) observed in the cerebral spinal fluid (CSF) of patients treated for three months with IONIS-HTT Rx (RG6042) at the two highest doses tested with mHTT levels
Toggle Summary Ionis Reports Fourth Quarter and Full Year 2017 Financial Results
SPINRAZA launch one of the most successful in rare disease history FY 2017 GAAP operating income of $25M; FY 2017 pro forma operating income of $111M 2017 year-end cash over $1B Mid-2018 launches planned for inotersen and volanesorsen Conference call and webcast today, February 27, 2018, at 11:30

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright Nasdaq. Minimum 15 minutes delayed.